The Value of Repeated BIOMarker Measurements During an SBT to Predict EXtubation Failure in ICU Patients
Launched by HENRIK ENDEMAN · Nov 24, 2022
Trial Information
Current as of January 13, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how measuring certain biomarkers (substances in the body that can indicate health conditions) during a specific test called a Spontaneous Breathing Trial (SBT) can help predict whether patients in the Intensive Care Unit (ICU) will be able to successfully breathe without a ventilator after being on mechanical ventilation. The goal is to improve patient care by identifying those who might struggle to breathe on their own, allowing for better planning and treatment.
To participate in this trial, individuals must be at least 18 years old and have been on a ventilator for more than 48 hours. They should also meet specific criteria that suggest they are ready to try breathing on their own again. Participants will undergo biomarker testing during the SBT and will need to provide consent, either personally or through a legal representative. It’s important to note that patients with certain complications or serious illnesses may not be eligible. Overall, this study aims to enhance the safety and effectiveness of weaning patients off mechanical ventilation in the ICU.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged ≥18 years
- • Mechanically ventilated for more than 48 hours
- • Fulfilling readiness-to wean criteria
- • Written informed consent from the patient or his/her legal representative
- Exclusion Criteria:
- • Patients with risk factors for laryngeal oedema and a negative cuff leak test (indicating upper airway obstruction with need for steroid treatment)
- • Planned replacement of the endotracheal tube for a tracheostomy
- • Terminal illness
Trial Officials
H. Endeman, Dr.
Principal Investigator
Erasmus Medical Center
About Henrik Endeman
Henrik Endeman is a dedicated clinical trial sponsor committed to advancing medical research through innovative and ethical study designs. With a strong focus on patient safety and regulatory compliance, Endeman fosters collaboration among researchers, healthcare professionals, and stakeholders to facilitate the development of groundbreaking therapies. Leveraging extensive expertise in clinical operations and strategic planning, he aims to streamline trial processes and enhance data integrity, ultimately contributing to the improvement of health outcomes and the acceleration of drug development.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rotterdam, Zuid Holland, Netherlands
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials